Drug Profile
XY 1029
Alternative Names: XY1029Latest Information Update: 03 Mar 2010
Price :
$50
*
At a glance
- Originator Xytis
- Class
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 03 Mar 2010 Discontinued - Preclinical for Anxiety disorders in Switzerland (unspecified route)
- 30 Mar 2006 Preclinical trials in Anxiety disorders in Switzerland (unspecified route)